Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T
Authors:
- Günther GrabnerGGGünther Grabner
- Iris NöbauerINIris Nöbauer
- Katarzyna ElandtKEKatarzyna Elandt
- Claudia KronnerwetterCKClaudia Kronnerwetter
- Adelheid WoehrerAWAdelheid Woehrer
- Christine MarosiCMChristine Marosi
- Daniela PrayerDPDaniela Prayer
- Siegfried TrattnigSTSiegfried Trattnig
- Matthias PreusserMPMatthias Preusser
- 1 January 2012
- journal article
- case report
- Published by Elsevier in Magnetic Resonance Imaging
- Vol. 30 (1) , 139-147
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Current concepts and management of glioblastomaAnnals of Neurology, 2011
- A population‐specific symmetric phase model to automatically analyze susceptibility‐weighted imaging (SWI) phase shifts and phase symmetry in the human brainJournal of Magnetic Resonance Imaging, 2009
- Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastomaNeurology, 2009
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Bevacizumab for recurrent malignant gliomasNeurology, 2008
- Age, gender, and hemispheric differences in iron deposition in the human brain: An in vivo MRI studyNeuroImage, 2008
- Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brainJournal of Magnetic Resonance Imaging, 2007
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Imaging iron stores in the brain using magnetic resonance imagingMagnetic Resonance Imaging, 2005
- Susceptibility weighted imaging (SWI)Magnetic Resonance in Medicine, 2004